FDA Clears First Laboratory Test for Anthrax

Article

GAITHERSBURG, Md. -- Tetracore, Inc. announced

today that it has received 510(K) clearance from the Food

and Drug Administration (FDA) for RedLine Alert, an antibody-based test

kit for use as an aid in the clinical laboratory identification of Bacillus

anthracis colonies from culture plates.

B. anthracis is the causative agent

of anthrax. The test is a lateral flow immunoassay containing a monoclonal

antibody which is specific for the presence of a cell surface protein found in

Bacillus anthracis vegetative cells. The test can be used on colonies as

early as 12 hours old. Attended time takes as little as 10 minutes and the

test can be fully completed within 20 minutes. In data submitted to the FDA on

145 Bacillus anthracis isolates, the RedLine Alert percentage correct was 98.6 percent; these isolates originated from 28 countries world-wide. This compared favorably to

another well recognized confirmatory test called gamma phage lysis, which can

require an additional day of culture to perform, whose percentage correct was 97.2 percent.

In addition, the RedLine Alert Test had an accuracy of 100 percent in correctly

differentiating B. anthracis from 49 other non-hemolytic Bacillus.

Dr. Beverly L. Mangold of Tetracore commented, "We are excited to be able to

provide a significant new clinical and public health tool to aid in protecting

against bio-terrorism threats."

Tetracore is a biotechnology R&D and product company whose mission is to

create and develop highly innovative diagnostic reagents and assays for

infectious diseases and bio-terrorism threat agents. Areas of company focus

include clinical, veterinary, and domestic preparedness testing.

Source: Tetracore, Inc.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.